Insulin analogues: new therapies for type 2 diabetes mellitus.
Insulin therapy is ultimately necessary for the control of blood glucose in a majority of patients with type 2 diabetes mellitus. Unfortunately, the pharmacokinetic characteristics of previously available rapid-, intermediate-, and long-acting preparations make sustained normoglycemia almost impossi...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1797083113232269312 |
|---|---|
| author | Bethel, M Feinglos, M |
| author_facet | Bethel, M Feinglos, M |
| author_sort | Bethel, M |
| collection | OXFORD |
| description | Insulin therapy is ultimately necessary for the control of blood glucose in a majority of patients with type 2 diabetes mellitus. Unfortunately, the pharmacokinetic characteristics of previously available rapid-, intermediate-, and long-acting preparations make sustained normoglycemia almost impossible. Advances in molecular genetic engineering have made possible the development of insulin analogues with pharmacokinetics that more closely mimic the needs of patients with type 2 diabetes. In the following article, we explore the insulin analogues currently available for clinical use, their pharmacokinetics, and the rationale for their use in the treatment of type 2 diabetes, and follow-up with a brief examination of future developments. |
| first_indexed | 2024-03-07T01:37:18Z |
| format | Journal article |
| id | oxford-uuid:95a81c0a-09f6-4de3-a0d1-6475af993cd3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:37:18Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:95a81c0a-09f6-4de3-a0d1-6475af993cd32022-03-26T23:47:30ZInsulin analogues: new therapies for type 2 diabetes mellitus.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:95a81c0a-09f6-4de3-a0d1-6475af993cd3EnglishSymplectic Elements at Oxford2002Bethel, MFeinglos, MInsulin therapy is ultimately necessary for the control of blood glucose in a majority of patients with type 2 diabetes mellitus. Unfortunately, the pharmacokinetic characteristics of previously available rapid-, intermediate-, and long-acting preparations make sustained normoglycemia almost impossible. Advances in molecular genetic engineering have made possible the development of insulin analogues with pharmacokinetics that more closely mimic the needs of patients with type 2 diabetes. In the following article, we explore the insulin analogues currently available for clinical use, their pharmacokinetics, and the rationale for their use in the treatment of type 2 diabetes, and follow-up with a brief examination of future developments. |
| spellingShingle | Bethel, M Feinglos, M Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title_full | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title_fullStr | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title_full_unstemmed | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title_short | Insulin analogues: new therapies for type 2 diabetes mellitus. |
| title_sort | insulin analogues new therapies for type 2 diabetes mellitus |
| work_keys_str_mv | AT bethelm insulinanaloguesnewtherapiesfortype2diabetesmellitus AT feinglosm insulinanaloguesnewtherapiesfortype2diabetesmellitus |